Stocks · News reference
Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $6
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5.5 to $6.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
IGC Pharma Announces Completion Of 168-Patient Enrollment In Phase 2 Trial Of IGC-AD1 For Alzheimer's Agitation; Topline Data Expected Q4 2026
'Federal Court Rejects Marijuana Opponents’ Request To Block Trump’s Rescheduling Move' - Marijuana Moment
https://www.marijuanamoment.net/federal-court-rejects-marijuana-opponents-request-to-block-trumps-rescheduling-move/
President And Founder Of Seabreeze Capital Partners LP Dougie Kass Posts On X "We have moved to super size $MSOS and individual cannabis stocks in the belief that a favorable rescheduling announcement will come shortly."
https://x.com/DougKass/status/2093394146182480247